Praxis Precision Medicines (PRAX) Cash & Current Investments (2019 - 2026)

Praxis Precision Medicines' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $786.9 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 139.9% year-over-year to $786.9 million; the TTM figure through Mar 2026 stood at $786.9 million (up 139.9% YoY), while the FY2025 annual figure was $599.3 million, up 52.67% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $786.9 million, up from $599.3 million in the prior quarter.
• The five-year high for Cash & Current Investments was $786.9 million in Q1 2026, with the low at $56.0 million in Q2 2022.
• The 5-year median for Cash & Current Investments is $207.4 million (2024), against an average of $249.2 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments tumbled 68.14% in 2022, then surged 382.86% in 2024.
• Praxis Precision Medicines' Cash & Current Investments stood at $61.6 million in 2022, then soared by 31.95% to $81.3 million in 2023, then soared by 382.86% to $392.6 million in 2024, then soared by 52.67% to $599.3 million in 2025, then soared by 31.29% to $786.9 million in 2026.
• Business Quant data shows PRAX's Cash & Current Investments at $786.9 million in Q1 2026, $599.3 million in Q4 2025, and $267.2 million in Q3 2025.